HIPK2 inhibition has been shown to increase tumor progression and resistance to therapies by, for instance, activation of the β4 integrin signaling pathway and of the HIF-1-mediated cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) axis [49,50,51]. The gene discussed is PTGS2; the disease is neoplasm.